Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- PMN.TO
- Price
- -
- Stock movement down
- -0.24 (-3.85%)
- Company name
- Promis Neurosciences Inc
- Exchange
- (TO ,
- Currency
- CAD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 51.48M
- Ent value
- 58.75M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 146.83%
- 1 year return
- -16.67%
- 3 year return
- -20.63%
- 5 year return
- -23.02%
- 10 year return
- -11.77%
Last updated: 2024-12-17
DIVIDENDS
PMN.TO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 8.58M |
| EPS (TTM) | -2.04 |
| FCF per share (TTM) | -1.98 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -24.41M |
| Net income (TTM) | -17.46M |
| EPS (TTM) | -2.04 |
| EPS (1y forward) | -1.82 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 3.33M |
| Net receivables | 41.52K |
| Total current assets | 4.41M |
| Goodwill | 0.00 |
| Intangible assets | 19.67K |
| Property, plant and equipment | 0.00 |
| Total assets | 4.43M |
| Accounts payable | 6.99M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 8.71M |
| Total liabilities | 10.61M |
| Shareholder's equity | -6.18M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -16.18M |
| Capital expenditures (TTM) | 106.00 |
| Free cash flow (TTM) | -16.98M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -394.36% |
| Return on Invested Capital | 282.62% |
| Cash Return on Invested Capital | 274.83% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| PMN.TO | S&P500 | |
| Current price drop from All-time high | -92.42% | -5.34% |
| Highest price drop | -97.73% | -56.47% |
| Date of highest drop | 24 Jun 2015 | 9 Mar 2009 |
| Avg drop from high | -69.11% | -11.07% |
| Avg time to new high | 17 days | 12 days |
| Max time to new high | 3942 days | 1805 days |
COMPANY DETAILS
Marketcap
51.48M
Marketcap category
Small-cap
Description
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Employees
6
Investor relations
-
SEC filings
CEO
Country
Canada
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found